Company News Summary | 06 May 2021
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
CSL Provides an Update on Agreement with uniQure
14:17:00 | Associate analysts
Original annuncemenet:Update on CSL Agreement with uniQure
CSL provided an update stating that the company announced the closing of the company's global commercialisation and license agreement with uniQure for etranacogene dezaparvovec (AMT-061), a novel gene therapy for the treatment of haemophilia B. The company stated that the global licensing agreement was announced on 24 June 2020 and the closing follows the completion of antitrust reviews of the transaction in the US, the UK and Australia. The company also reported that under the terms of the agreement, uniQure will receive an cash payment of US$450 million by 13 May, 2021.
|This report appeared on www.morningstar.com.au||2021 Morningstar Australasia Pty Limited|
© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").